Certuity LLC Has $7.28 Million Holdings in Bristol Myers Squibb Company (NYSE:BMY)

Key Points

• Certuity LLC reduced its holdings in Bristol Myers Squibb by 11.4%, selling 15,351 shares during the first quarter, leaving them with a total of 119,281 shares valued at approximately $7,275,000.
• Several institutional investors have significantly increased their stakes in Bristol Myers Squibb, with Ameriprise Financial Inc. raising its holdings by 59.9% and GQG Partners LLC boosting theirs by an astounding 22,647.6%.
• Bristol Myers Squibb recently reported a quarterly EPS of $1.46, surpassing analysts' expectations and generating $12.27 billion in revenue, marking a 0.6% increase compared to the same quarter last year.

Certuity LLC lessened its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 11.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 119,281 shares of the biopharmaceutical company's stock after selling 15,351 shares during the period. Certuity LLC's holdings in Bristol Myers Squibb were worth $7,275,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Pinney & Scofield Inc. purchased a new position in shares of Bristol Myers Squibb during the 4th quarter worth $25,000. Park Square Financial Group LLC purchased a new position in Bristol Myers Squibb during the 4th quarter valued at about $26,000. Transce3nd LLC purchased a new position in Bristol Myers Squibb during the 4th quarter valued at about $28,000. Global Wealth Strategies & Associates boosted its holdings in Bristol Myers Squibb by 137.5% during the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 275 shares during the period. Finally, Harel Insurance Investments & Financial Services Ltd. purchased a new position in Bristol Myers Squibb during the 1st quarter valued at about $31,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on BMY shares. Citigroup reduced their price target on Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a research report on Friday, August 1st. Jefferies Financial Group dropped their target price on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. William Blair restated a "market perform" rating on shares of Bristol Myers Squibb in a research note on Friday, April 25th. Morgan Stanley reiterated a "hold" rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Finally, Daiwa Capital Markets downgraded Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price objective on the stock. in a research report on Tuesday, August 5th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $56.38.

Bristol Myers Squibb Stock Performance

Shares of NYSE BMY traded up $0.64 during trading hours on Friday, hitting $48.45. 11,206,898 shares of the company's stock were exchanged, compared to its average volume of 12,717,643. The stock has a market capitalization of $98.62 billion, a price-to-earnings ratio of 19.54, a PEG ratio of 2.48 and a beta of 0.36. Bristol Myers Squibb Company has a 1-year low of $42.96 and a 1-year high of $63.33. The company's 50-day moving average price is $47.23 and its 200-day moving average price is $51.45. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, beating analysts' consensus estimates of $1.07 by $0.39. The company had revenue of $12.27 billion for the quarter, compared to the consensus estimate of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%. The firm's quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.07 EPS. On average, sell-side analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd were paid a $0.62 dividend. The ex-dividend date of this dividend was Thursday, July 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.1%. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 100.00%.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.